

Biophytis Presented A Poster at The Association for Research in Vision and Ophthalmology Annual Meeting

Paris, France, May 2, 2019, - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced it presented a poster at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Vancouver, Canada, held from April 28 to May 2, 2019.

The poster highlights the potential mechanism of action of Macuneos (BIO201), the Company's preclinical product candidate for the treatment of retinopathies, including dry age-related macular degeneration (AMD). In this cellular model, we observed that Macuneos (BIO201) counteracts the phototoxicity induced by A2E accumulation by a selective stimulation of the transrepression activity of PPAR α and PPAR β/δ . A2E is a sub-product of the visual pigment cycle, that is phototoxic to the retina and is known to be a key factor for the retina degeneration in AMD and Stargardt disease.

Poster details can be found below:

Poster Session: AMD and Antiangiogenic agents

Title: **BIO201 Protects Retinal Pigment Epithelium Against A2E-Induced Phototoxicity Through A Mechanism Involving The PPARS**

Poster No.: B0081

Presenters: Valerie Fontaine and Serge Camelo

Date/Time: Wednesday, May 1, 2019 at 3:00- 4:45 p.m. / West Exhibition Hall

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit www.biophytis.com.

Disclaimer

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

Biophytis Investor Relations Contact

Daniel Schneiderman, CFO
dan.schneiderman@biophytis.com
Tel: +1 (857) 220-9720

U.S. Media Contact

LifeSci Public Relations
Cherilyn Cecchini, M.D.
cecchini@lifescipublicrelations.com
Tel: +1 (646) 876-5196

Europe Media Contact

Citigate Dewe Rogerson
Laurence BAULT/Antoine DENRY

laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogerson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

Source: Biophytis SA